Circulation. Cardiovascular imaging
-
Circ Cardiovasc Imaging · Jul 2013
Randomized Controlled TrialEchocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.
Lorcaserin is a selective 5-HT2C agonist evaluated for weight management in clinical trials. Echocardiographic monitoring was conducted to test the hypothesis that selective 5-HT2C agonism would avoid valvular heart disease. ⋯ URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00395135, NCT00603291, NCT00603902.
-
Circ Cardiovasc Imaging · Jul 2013
Randomized Controlled Trial Multicenter StudyPercutaneous mitral valve repair in the initial EVEREST cohort: evidence of reverse left ventricular remodeling.
Percutaneous repair of mitral regurgitation (MR) permits examination of the effect of MR reduction without surgery and cardiopulmonary bypass on left ventricular (LV) dimensions and function. The goal of this analysis was to determine the extent of reverse remodeling at 12 months after successful percutaneous reduction of MR with the MitraClip device. ⋯ URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00209339, NCT00209274.
-
Circ Cardiovasc Imaging · Jul 2013
Multicenter StudyEchocardiographic features defining right dominant unbalanced atrioventricular septal defect: a multi-institutional Congenital Heart Surgeons' Society study.
Definition and management of right dominant unbalanced atrioventricular septal defect (AVSD) remains challenging because unbalance entails a spectrum of left heart hypoplasia. Previous work has highlighted atrioventricular valve (AVV) index as a reasonable defining echocardiographic measure. We sought to assess which additional echocardiographic features might provide further characterization. ⋯ The angle of right ventricle/LV inflow and other surrogates of inflow may be important defining echocardiographic measures of right dominant unbalanced AVSD, although confirmation is needed.